NCT02957409 (PARTHENON) is a clinical trial of sacubitril/valsartan in Heart Failure, sponsored by Novartis Pharmaceuticals.

Who is sponsoring NCT02957409?

NCT02957409 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT02957409?

Interventions in NCT02957409: sacubitril/valsartan.

What condition does NCT02957409 study?

NCT02957409 studies Heart Failure.

Is NCT02957409 still recruiting?

NCT02957409 is currently completed. Last updated 26 August 2021.

Last reviewed 2021-08-26 · How we verify

NCT02957409: PARTHENON

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PAtient RegisTry Assessing Effectiveness and Safety of HEart Failure treatmeNt With LCZ696 acrOss CaNada

Completed Last updated 26 August 2021

What this trial tests

trial testing sacubitril/valsartan in Heart Failure in 1,009 participants. Completed in 24 October 2020.

Timeline

20 May 2016

Primary endpoint
24 October 2020

24 October 2020

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,009
Start date	20 May 2016
Primary completion	24 October 2020
Estimated completion	24 October 2020
Sites	32 locations across Canada

Drugs / interventions tested

sacubitril/valsartan

Conditions studied

Heart Failure — all drugs for Heart Failure →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to describe the heart failure with reduced ejection fraction (HFrEF) patient population receiving sacubitril/valsartan treatment.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Sacubitril/valsartan in cardiovascular disease: evidence to date and place in therapy.
Yandrapalli S, Khan MH, Rochlani Y, Aronow WS. · · 2018 · cited 19× · PMID 29921166 · DOI 10.1177/1753944718784536
Cost-Effectiveness of Earlier Transition to Angiotensin Receptor Neprilysin Inhibitor in Patients With Heart Failure and Reduced Ejection Fraction.
Grant ADM, Chew DS, Howlett JG, Miller RJH. · · 2020 · cited 9× · PMID 33305203 · DOI 10.1016/j.cjco.2020.05.009
Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan.
Liu RC. · · 2018 · cited 5× · PMID 29850980 · DOI 10.1007/s40256-018-0280-5

Verify or expand the search:

Other trials of sacubitril/valsartan

Trials testing the same drug.

NCT06149104 — A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle · Phase 3 · completed
NCT05870709 — Real World, Pharmacy-assessed Adherence to New Onset Entresto® (Sacubitril/Valsartan) in Patients With Chronic Heart Fai · withdrawn
NCT05613140 — Sacubitril/Valsartan Treated Adult Patients With Chronic Heart Failure · completed
NCT06218199 — Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts · Phase 4 · recruiting
NCT04637555 — Open-label Extension Study for CLCZ696G2301 (PARADISE-MI) · Phase 3 · withdrawn

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02957409 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 26 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02957409.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing